Navigation Links
Sevelamer in Medical News

Nephrologists Indicate High Interest in AMAG Pharmaceuticals' Newly Approved Feraheme According to Latest BioTrends Report

...ge over Amgen's Aranesp on "minimal hassles with prior authorizations" and "adequate reimbursement". In the phosphate binder market, Genzyme's sevelamer compounds are being used to treat almost half of the dialysis patients. At one year post launch, virtually all Nephrologists have started to use Renv...

Product Shifts are Occurring in the Renal Anemia and Bone and Mineral Metabolism Markets According to the Most Recent TreatmentTrends(R): US Nephrology Report from BioTrends Research Group

... hemodialysis patients on Renvela compared to 67% in the previous quarter. sevelamer is the market leader in dialysis with 55% share. Among CKD patients, sevelamer and FMC's PhosLo each have approximately 36% market share. In both the dia...

Cutting Phosphate May Protect Kidney Patients From Heart Trouble

.... Food and Drug Administration recently decided to extend the label of phosphate-binding drugs on the market. These drugs -- calcium acetate (PhosLo), sevelamer (Renagel) and lanthanum carbonate (Fosrenol) -- will now be labeled to indicate they are approved for treatment of high serum phosphate levels in CKD...

Readily available treatment could help prevent heart disease in kidney patients

...dy and others like it, the Food and Drug Administration has recently decided to extend the label of such drugs. As a result, calcium acetate (PhosLo), sevelamer (Renagel) and lanthanum carbonate (Fosrenol) will be labeled to indicate they are approved for treatment of high serum phosphate levels in patients wi...

Genzyme Delivers Strong Fourth Quarter to Conclude Outstanding Year

...$1.24 billion this year, compared with $1.13 billion in 2007. -- Sales of sevelamer therapies Renagel(R) (sevelamer hydrochloride) and Renvela(R) (sevelame... sNDA for this indication. A CKD indication will expand the market for sevelamer and help sustain the long-term growth of the Renal franchise. -- Sale...
Sevelamer in Medical Technology

Genzyme Announces Results of Clinical Trials Investigating Powder Form of Sevelamer Carbonate

CAMBRIDGE, Mass., June 18, 2007 /PRNewswire-FirstCall/ -- Genzyme Corp. today announced the results of two new studies comparing a powder form of Renvela (sevelamer carbonate) to Renagel tablets (sevelamer hydrochloride), including one trial in which patients received the powder form three times p...

Genzyme Announces Results of Clinical Trials Investigating Powder Form of Sevelamer Carbonate

CAMBRIDGE, Mass., June 18, 2007 - Genzyme Corp. (Nasdaq: GENZ) today announced the results of two new studies comparing a powder form of Renvela™ (sevelamer carbonate) to Renagel® tablets (sevelamer hydrochloride), including one trial in which patients received the powder form three time...

Genzyme Announces Successful Completion of Study Investigating Sevelamer Carbonate in Patients With Chronic Kidney Disease

...nounced today represent one portion of a comprehensive clinical program for sevelamer carbonate. Data showing the equivalence of sevelamer carbonate and sevelamer hydrochloride were presented last week at the sprin...
Sevelamer in Biological Technology

Keryx Biopharmaceuticals Reports Positive Phase 2 Study Results of Zerenex (Ferric Citrate) for the Treatment of Hyperphosphatemia in End-Stage Renal Disease Patients

...sules per day of calcium acetate, calcium carbonate, lanthanum carbonate or sevelamer hydrochloride or any combination of these agents were eligible for enrollme...sules per day of calcium acetate, calcium carbonate, lanthanum carbonate or sevelamer hydrochloride or any combination of these agents were eligible for enrollme...

ChartTrends(R): Bone and Mineral Metabolism in Dialysis Reveals Latest Trends in the Treatment of Calcium, Phosphorus and PTH

...ted data, combination binder therapy is prescribed infrequently. Genzyme's sevelamer is the market share leader despite the fact that it has the highest pill bu... lower persistency compared to Renagel, Tums and FMC's PhosLo. Within the sevelamer franchise, patient conversion to Renvela stands at about 27% and about half...

BioTrends Releases TreatmentTrends(TM): US Nephrology, an Ongoing Syndicated Publication Providing Insight into Physician Perceptions and Management of Renal Anemia, Hyperphosphatemia, and Secondary Hyperparathyroidism

...Genzyme's Renvela in Q108. Although the growth of Renvela seems to be fueled by cannibalization of Renagel, Nephrologists expect increases in overall sevelamer share in both dialysis and CKD, as well as increases in Shire's Fosrenol, while continued shifts are expected away from calcium based binders. T...

BioTrends Releases TreatmentTrends(TM): Nephrology and Renal Dietitians, Two Syndicated Reports Providing Continuing Insight into the Management of Renal Anemia, Hyperphosphatemia, and Secondary Hyperparathyroidism

...hate binder market, the introduction of Genzyme's Renvela has given overall sevelamer share a boost compared to the same quarter last year, although most of the ...n the two most frequently prescribed binders among dialysis patients. While sevelamer has the highest share across all types of dialysis units, Shire's Fosrenol ...

BioTrends Releases Quarterly TreatmentTrends(TM): Nephrology Report Highlighting Market Trends for Renal Anemia, Hyperphosphatemia, and Secondary Hyperparathyroidism

...enzyme's Renvela is beginning to shift market share in both dialysis and CKD segments. While Renvela has primarily cannibalized Renagel share, overall sevelamer share in both dialysis and CKD has increased compared to the prior year. Despite sevelamer's increased share, for the first time, overall satisfaction...

Genzyme Reports Strong Second-Quarter Growth

...nosis of thyroid cancer and its international adoption is being driven by expansion into new geographic markets. Within the Renal business, sales of sevelamer therapies Renagel(R) (sevelamer hydrochloride) and Renvela grew 16 percent to $168.6 million from $144.9 million in the second quarter last year. Genz...

BioTrends Releases Two Publications - TreatmentTrends(TM): Nephrologists and TreatmentTrends(TM): Renal Dietitians - Highlighting Market Trends for Renal Anemia, Hyperphosphatemia, and Secondary Hyperparathyroidism

...cal advantages over Renagel and project that Renvela, while primarily cannibalizing share from Renagel, will increase the overall market share for the sevelamer franchise. BioTrends will publish Wave II of LaunchTrends(TM): RENVELA on May 9th. In the management of secondary hyperparathyroidism, while about h...

Genzyme Reports Strong First-Quarter Growth

...also contributing to the product's growth, following the December 2007 U.S. approval for this indication. -- Within the Renal business, sales of sevelamer therapies Renagel(R) (sevelamer hydrochloride) and Renvela grew 23 percent to $168.7 million from $137.4 million in the first quarter last yea...

Genzyme Launches Renvela(R) in the U.S. for Dialysis Patients

...ed risk of cardiovascular morbidity and mortality. sevelamer provides the added benefit of significant LDL cholesterol reduction. sevelamer is the only phosphate binder available that does n...s for Bone Metabolism and Disease in CKD recommend sevelamer as a first-line treatment option to control phosph...

FDA Approves Genzyme's Renvela(TM) for Dialysis Patients

...ed risk of cardiovascular morbidity and mortality. sevelamer provides the added benefit of significant LDL cholesterol reduction. sevelamer is the only phosphate binder available that does n...s for Bone Metabolism and Disease in CKD recommend sevelamer as a first-line treatment option to control phosph...
Other Tags
(Date:7/10/2014)... July 11, 2014 The Capital Institute ... performed the first procedure in a clinical trial that ... in the leg. , During the procedure, done at ... an endovascular neurosurgeon, threaded a tiny catheter through the ... body and neck and into the brain. Once the ...
(Date:7/10/2014)... More than 200 experts on aggression, who research issues ... attend the 21st World Meeting of the International ... Loews Atlanta Hotel, July 15-19. , Georgia State ... is held every other year on alternating continents. , ... from more than 20 different countries, which will help ...
(Date:7/10/2014)... Ticketability.com has a wide array of tickets for the successful ... Diego are being added to the inventory. The star has ... added September 28 show is drawing a great deal of ... view the selection of discounted seats at Ticketability.com. , Paul ... the general public on July 18 at 10:00 a.m. Fans ...
(Date:7/10/2014)... D.C. (PRWEB) July 10, 2014 One ... for Bangladesh Worker Safety announced today it will extend ... to four months’ wages for workers displaced as a ... To date, Alliance inspections have resulted in the closure ... in all five cases, raising immediate safety concerns. In ...
(Date:7/10/2014)... According to a new market ... (Land, Airborne, Naval), Application (Software Defined Radios, SATCOM, ... (North America, Asia-Pacific, Europe, the Middle East & ... MarketsandMarkets, the market is estimated to be $30.15 ... a CAGR of 5.56% to reach $39.52 billion ...
Breaking Medicine News(10 mins):Health News:New Trial Delivers Chemotherapy to Brain Tumor Through Artery in Leg 2Health News:New Trial Delivers Chemotherapy to Brain Tumor Through Artery in Leg 3Health News:Georgia State Hosts National Conference On Aggression 2Health News:Georgia State Hosts National Conference On Aggression 3Health News:Georgia State Hosts National Conference On Aggression 4Health News:Paul McCartney Tickets for San Diego: Ticketability.com Announces Discounted Tickets for McCartney’s Tour Stop at Petco Park on September 28 2Health News:Alliance for Bangladesh Worker Safety to Double Compensation for Displaced Factory Workers; Members Vote to Extend Wage Benefits from Two to up to Four Months 2Health News:Portable Communication Systems Market Projected to Reach $39.52 Billion by 2019 - New Report by MarketsandMarkets 2Health News:Portable Communication Systems Market Projected to Reach $39.52 Billion by 2019 - New Report by MarketsandMarkets 3Health News:Portable Communication Systems Market Projected to Reach $39.52 Billion by 2019 - New Report by MarketsandMarkets 4
(Date:7/10/2014)... at NJIT,s business incubator, received a $1.4 million federal ... use to staunch bleeding during brain surgery. , Surgeons ... the natural bio-polymer solutions in the gel will cohere ... , The gel can shorten an intracranial surgery ... time for the patient,s skull to be open and ...
(Date:7/10/2014)... family of enzymes known as heme enzymes, due to ... site. At the centre of the heme cofactor is ... a reacting heme is in an intermediate state called ... decades is whether this oxidation involves just an oxygen ... fundamental question has implications for understanding oxidative processes within ...
(Date:7/10/2014)... Society (ACS) announced today that Courtney Aldrich, Ph.D., ... Infectious Diseases as editor-in-chief. With the first ... pioneering journal will meet a growing demand for ... research. , "Our vision is to develop a ... on the basic science that advances the field ...
Breaking Biology News(10 mins):A start-up at NJIT develops bleeding-control gel for brain surgery 2Neutron crystallography solves long-standing biological mystery 2Neutron crystallography solves long-standing biological mystery 3ACS Infectious Diseases: Unique chemistry journal names editor 2
Other Contents